Jubayer Rahman, Jack A. Bibby, Parul Singh, Nicolas S. Merle, Erin E. West, Andrea Bohrer, Katrin Mayer-Barber, Chengyu Liu, Lauren R. Brinster, Behdad Afzali, Ana M. Briones, Sara Alehashemi, Farzana Bhuyan, Jiahui Ge, Xijian Chen, Yingbi Zhou, Murray C.H. Clarke, Bin Liu, Raphaela Goldbach-Mansky, C. Henrique Serezani, Claudia Kemper
{"title":"A CD4+ T cell-intrinsic complement C5aR2-prostacyclin-IL-1R2 axis orchestrates Th1 cell contraction","authors":"Jubayer Rahman, Jack A. Bibby, Parul Singh, Nicolas S. Merle, Erin E. West, Andrea Bohrer, Katrin Mayer-Barber, Chengyu Liu, Lauren R. Brinster, Behdad Afzali, Ana M. Briones, Sara Alehashemi, Farzana Bhuyan, Jiahui Ge, Xijian Chen, Yingbi Zhou, Murray C.H. Clarke, Bin Liu, Raphaela Goldbach-Mansky, C. Henrique Serezani, Claudia Kemper","doi":"10.1016/j.immuni.2025.05.003","DOIUrl":null,"url":null,"abstract":"T helper 1 (Th1) cell initiation pathways are well characterized; however, those regulating their contraction are less understood. Here, we define a CD4<sup>+</sup> T cell-autonomous pathway in which complement C5 orchestrated a shift from prostaglandin E2 (PGE2) dominance to enhanced prostacyclin (PGI2) production via activation of C5a receptor 2 (C5aR2). This pivot in lipid mediators induced autocrine signaling through the PGI2 receptor and expression of the interleukin-1 (IL-1) decoy IL-1 receptor type 2 (IL-1R2), which sequestered Th1 cell-driving intrinsic IL-1β, facilitating Th1 cell contraction. Disruption of this C5aR2-PGI2-R axis was a hallmark of pathologically persistent Th1 cell activity in inflammatory conditions, including cryopyrin-associated periodic syndromes (CAPS), Crohn’s disease, and rheumatoid arthritis. Rebalancing this axis through selective PGE2 synthase inhibition rectified the hyperactive Th1 cell phenotype <em>in vitro</em> in T cells from individuals with CAPS. Therefore, complement is a key controller of prostanoid metabolism, and the latter is an intrinsic—and potentially druggable—checkpoint for the cessation of Th1 cell effector responses.","PeriodicalId":13269,"journal":{"name":"Immunity","volume":"172 1","pages":""},"PeriodicalIF":25.5000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.immuni.2025.05.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
T helper 1 (Th1) cell initiation pathways are well characterized; however, those regulating their contraction are less understood. Here, we define a CD4+ T cell-autonomous pathway in which complement C5 orchestrated a shift from prostaglandin E2 (PGE2) dominance to enhanced prostacyclin (PGI2) production via activation of C5a receptor 2 (C5aR2). This pivot in lipid mediators induced autocrine signaling through the PGI2 receptor and expression of the interleukin-1 (IL-1) decoy IL-1 receptor type 2 (IL-1R2), which sequestered Th1 cell-driving intrinsic IL-1β, facilitating Th1 cell contraction. Disruption of this C5aR2-PGI2-R axis was a hallmark of pathologically persistent Th1 cell activity in inflammatory conditions, including cryopyrin-associated periodic syndromes (CAPS), Crohn’s disease, and rheumatoid arthritis. Rebalancing this axis through selective PGE2 synthase inhibition rectified the hyperactive Th1 cell phenotype in vitro in T cells from individuals with CAPS. Therefore, complement is a key controller of prostanoid metabolism, and the latter is an intrinsic—and potentially druggable—checkpoint for the cessation of Th1 cell effector responses.
期刊介绍:
Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.